Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Feb 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Feb 2026.
25 Nov 2024 Planned primary completion date changed from 24 Nov 2025 to 1 Oct 2025.
24 Jul 2023 According to AbbVie media release, the first patient has been dosed in this trial and aims to enroll approximately 1,300 participants across 275 sites worldwide.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com